{"id":"NCT00415597","sponsor":"Pfizer","briefTitle":"Study of Embeda (Kadian NT, ALO-01) in Subjects With Chronic Moderate to Severe Nonmalignant Pain","officialTitle":"A Long-Term, Open-Label Safety Study of ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride Extended-Release) Capsules in Subjects With Chronic Moderate to Severe Nonmalignant Pain","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-12","primaryCompletion":"2008-03","completion":"2008-03","firstPosted":"2006-12-25","resultsPosted":"2009-10-29","lastUpdate":"2013-09-20"},"enrollment":467,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Pain"],"interventions":[{"type":"DRUG","name":"ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride ER)","otherNames":["Embeda"]}],"arms":[{"label":"ALO-01","type":"EXPERIMENTAL"}],"summary":"Open-Label, Safety Study to evaluate the long-term safety of Kadian NT (ALO-01) administered for up to 12 months.","primaryOutcome":{"measure":"Subjects With Treatment Emergent Adverse Events","timeFrame":"up to 12 months","effectByArm":[{"arm":"ALO-01","deltaMin":378,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":5},"locations":{"siteCount":58,"countries":["United States"]},"refs":{"pmids":["26695349","21904098","21075272"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":33,"n":465},"commonTop":["Constipation","Nausea","Headache","Vomiting","Somnolence"]}}